Holen Sie sich die Stockscreener-App
4.34
1.59%
-0.07
Handel nachbörslich:
4.32
-0.02
-0.46%
Arbutus Biopharma Corp Aktie (ABUS) Neueste Nachrichten
Arbutus Biopharma Corp (ABUS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Arbutus Biopharma Corp (ABUS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Arbutus Biopharma Corp (ABUS) Cash Flow - TradingKey
ABUS|Arbutus Biopharma Corp|Price:4.380|Chg%:-0.090 - TradingKey
Arbutus Biopharma Corp (ABUS) Balance Sheet - TradingKey
ABUS|Arbutus Biopharma Corp|Price:4.440|Chg%:+0.060 - TradingKey
TradingKey - TradingKey
Arbutus Biopharma Corp (ABUS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Arbutus Biopharma Corp (ABUS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Arbutus Biopharma Corp (ABUS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arbutus Biopharma Corp (ABUS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Arbutus Biopharma Corp (ABUS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Arbutus Plans $230M Buyback as Patent Fight Expands - MyChesCo
US Seeks Toss Of Arbutus Patent Suit Over Moderna Vaccine - Law360
Arbutus (ABUS) Secures $178 Million Settlement with Moderna - GuruFocus
Arbutus Biopharma (ABUS) Files 8-K Announcing Agreement Termination and Key Company Details - Minichart
Arbutus Biopharma (ABUS) Files Lawsuits Against Pfizer and BioNT - GuruFocus
Arbutus (ABUS) Plans Share Buyback Program Starting Q3 - GuruFocus
Arbutus Biopharma Files International Patent Lawsuits Against Pfizer and BioNTech, Announces Moderna Settlement Payment and Plans for Capital Return - Quiver Quantitative
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders - The Manila Times
Arbutus awards litigation bonuses to CEO Lindsay Androski; CFO Tuan Nguyen to receive discretionary bonus - TradingView
Arbutus Biopharma (Nasdaq: ABUS) receives $178M from Moderna, eyes $230M buyback - Stock Titan
Arbutus Biopharma (ABUS) Joins Russell Defensive Indexes And Exits Value Benchmarks - Yahoo Finance
Arbutus Biopharma stock hits 52-week high at 5.34 USD - Investing.com UK
Arbutus Biopharma stock hits 52-week high at 5.34 USD By Investing.com - Investing.com South Africa
ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week - Yahoo Finance
ABUS Stock Price, Quote & Chart - ChartMill
ABUSArbutus Biopharma Corp Options - Finviz
Gov't Says It Should Face Vax IP Claims, Not Moderna - Law360
Arbutus Biopharma Corp (ABUS) Institutional Confidence - TradingKey
Arbutus Biopharma Corp (ABUS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arbutus Biopharma (ABUS) Edges Higher on Improved Sentiment: Key Levels to WatchConversion Trade - DonanımHaber
Arbutus Biopharma Corporation (ABUS) Reports Q1 2026 Results - Insider Monkey
Arbutus Biopharma (ABUS) director awarded fully vested options on 78,800 shares - Stock Titan
Director at Arbutus Biopharma (ABUS) receives 78,800 fully vested stock options - Stock Titan
Arbutus Biopharma Holds Steady Near Midpoint of Trading RangeSymmetrical Triangle - dars.gov.et
Moderna Tells Fed. Circ. US Must Face COVID Vax Patent Case - Law360
ABUS Technical Analysis | Trend, Signals & Chart Patterns | ARBUTUS BIOPHARMA CORP (NASDAQ:ABUS) - ChartMill
Shareholders at Arbutus Biopharma (NASDAQ: ABUS) approve 2026 share plan and auditor - Stock Titan
Arbutus Posts Profit After Moderna Patent Settlement - MyChesCo
Two Seas (NASDAQ: ABUS) reports 18.56M Arbutus shares; 9.4% stake - Stock Titan
Arbutus Biopharma Corp Q1 2026 Financial Results and Business Update – Clinical Progress in Hepatitis B Therapies - Minichart
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):